{
    "clinical_study": {
        "@rank": "58710", 
        "arm_group": [
            {
                "arm_group_label": "EGP group", 
                "arm_group_type": "Experimental", 
                "description": "the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy"
            }, 
            {
                "arm_group_label": "GP group", 
                "arm_group_type": "Active Comparator", 
                "description": "the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators designed this study to evaluate the efficiency and the acute toxicities of\n      recombinant human endostatin (endostar) combined with chemotherapy in the metastatic\n      nasopharyngeal carcinoma (NPC)."
        }, 
        "brief_title": "Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Effects of Chemotherapy", 
            "Stage IVC Nasopharyngeal Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse\n      reaction of recombinant human endostatin (endostar) combined with chemotherapy to the\n      metastatic nasopharyngeal carcinoma (NPC)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  metastatic nasopharyngeal carcinoma 6 months after first treatment,never receive any\n             anticancer treatment except local radiotherapy to the bone metastasis\uff0cat least one\n             measurable metastatic lesions\uff0cECOG PS 0-1\uff0cElectrocardiogram (ecg) no special\n             abnormal\uff0ccomply with the test requirements, cooperate with regular follow-up.\n\n        Exclusion Criteria:\n\n          -  To give local treatment,clinical severe infection(>grade 2),with the central nervous\n             system metastases,ECOG PS\u22652,patients with pregnancy or breastfeeding,has a history of\n             peripheral nerve disease,concomitant with other serious diseases,ever or concomitant\n             with other serious diseases except for Cervical carcinoma in situ,cure of basal cell\n             carcinoma,bladder surface tumor,any cancer 3 years after curation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "362", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915134", 
            "org_study_id": "ZhejaingCH-npc-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "EGP group", 
                "description": "target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin\uff1a7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.", 
                "intervention_name": "Recombinant Human Endostatin plus gemcitabine and cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "Experimental: EGP group"
            }, 
            {
                "arm_group_label": "GP group", 
                "description": "only chemotherapy\uff1aGemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.", 
                "intervention_name": "Gemcitabine and cisplatin", 
                "intervention_type": "Drug", 
                "other_name": "No Intervention: GP group"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Endostatins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "nasopharyngeal carcinoma", 
            "Recombinant Human Endostatin", 
            "chemotherapy", 
            "gemcitabine and cisplatin"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "email": "libindoctor@163.com", 
                "last_name": "Bin Li", 
                "phone": "86-571-88122091"
            }, 
            "contact_backup": {
                "email": "fengxinglai@hotmail.com", 
                "last_name": "Xinglai Feng", 
                "phone": "86-571-88122092"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Bin Li", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage \u2162 Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma", 
        "other_outcome": {
            "description": "According to the most commonly used questionnaire EORTC QLQ C30 and H&N35 35 for evaluation", 
            "measure": "The quality of life assessment", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed for the duration of hospital stay,an expected average of 100 days and every 6 months thereafter for 3 years"
        }, 
        "overall_contact": {
            "email": "cxzfyun@sina.com", 
            "last_name": "Xiaozhong Chen", 
            "phone": "86-571-88122098"
        }, 
        "overall_contact_backup": {
            "email": "libindoctor@163.com", 
            "last_name": "Bin Li", 
            "phone": "86-571-88122091"
        }, 
        "overall_official": [
            {
                "affiliation": "Zhejiang Cancer Hospital", 
                "last_name": "Xiaozhong Chen", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Zhejiang Cancer Hospital   Hangzhou, Zhejiang, China  310022", 
                "last_name": "Xiaozhong Chen", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS means assignment to the date of any local or distant progress of the disease using Kaplan-Meier calculate the progress free survival rates,and find out is there significant difference between these two groups.", 
            "measure": "progress free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "2years after the inception assignment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "the overall survival denote to assignment to date of death from any cause. Using Kaplan-Meier to calculate the 2-year ,3-year,5-year overall survival rate,and find is there any significant difference between these two groups.", 
                "measure": "overall survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "1 year ,2 years and 3 years after the inception of the assignment"
            }, 
            {
                "description": "observe and record the toxicity profile(including but not limit to mucositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edition) during the neoadjuvant chemotherapy ,chemoradiation and follow-up.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 3 years"
            }
        ], 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital, School of Medicine, Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sir Run Run Shaw Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}